DIABETES CARE
Published on: 09.13.2017
Abbott (NYSE: ABT) today announced that the FreeStyle® Libre system is now available for reimbursement in the United Kingdom (UK). The National Health Service (NHS) Business Services Authority has approved the listing on the Drug Tariff for the FreeStyle Libre system for people with diabetes using insulin.
Published on: 08.31.2017
Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle® Libre glucose monitoring system effective September 1, 2017.
Published on: 07.13.2017
Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technologyi with Bigfoot's insulin delivery solutions in the United States.
Published on: 06.29.2017
Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes.
Published on: 05.08.2017
Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle® Libre—Abbott's revolutionary glucose monitoring technology that removes the need for routine finger sticks1 for people with diabetes.
Published on: 02.15. 2017
Abbott (NYSE: ABT) today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels.
Published on: 09.28. 2016
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes.
Published on: 02.16.2016
Today, Abbott (NYSE:ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology.
Published on: 02.04. 2016
Today, Abbott (NYSE: ABT) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old.
Published on: 04.15. 2015
The cost of insurance premiums and employee medical claims continues to rise in the United States, which is especially challenging for people living with chronic conditions such as diabetes.
ADC-01541 Ver 6.0 09/17
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
NO
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
NO